Goldman Sachs raised the firm’s price target on Kiniksa (KNSA) to $55 from $45 and keeps a Buy rating on the shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KNSA:
- Kiniksa Pharmaceuticals Reports Strong Q3 2025 Growth
- Kiniksa Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
- Kiniksa Pharmaceuticals: Strong Q3 Performance and Growth Potential Justify Buy Rating
- Kiniksa riases FY25 ARCALYST net product revenue view $670M-$675M
- Kiniksa expects current operating plan to remain cash flow positive